ArticleScientific reports2025
Risk and clinical implications of histological transformation in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: A population-based analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Histological response dynamics in gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue afterHaematologica · 2026Article
- Observational
- Checkpoint inhibition and beyond: Precision immune engineering for the immune-privileged landscape of ocular malignancies.BioImpacts : BI · 2026Review
- Prognostic outcome of extranodal marginal zone B-cell lymphoma: a nationwide cohort.Scientific reports · 2025Article
- Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States.Blood cancer journal · 2025Article
- Diagnostic challenges and management strategies of pulmonary mucosa-associated lymphoid tissue lymphoma: a case report and literature review.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) is the third most prevalent subtype of mature B-cell lymphomas. While MALT lymphoma typically has a favorable prognosis, the outlook can worsen dramatically if histological transformation (HT) occurs, usually into a more aggressive form like diffuse large B-cell lymphoma (DLBCL). Large-scale study with long-term follow-up specifically focused on the transformation of MALT lymphoma is limited. This study utilized the SEER database to analyze 20,944 patients diagnosed with MALT lymphoma from 2000 to 2020. We also included a cohort of de novo DLBCL patients for comparison. Our findings showed that HT occurred in 1.59% of MALT lymphoma cases, with 5- and 10-year cumulative incidences of 1.2% and 2.2%, respectively. Patients presenting with B symptoms, age ≥ 60, and advanced-stage disease were at a significantly higher risk for HT. The median time to transformation was 3.67 years. Both univariate and multivariate analyses demonstrated that age ≥ 60 was a significant adverse factor for lymphoma-specific survival (LSS) and overall survival (OS) following HT. This population-based study contributes to the characterization of transformation risk and outcomes in MALT lymphoma and may help inform clinical surveillance strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.